CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for Wegovy and Zepbound ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

But it does not appear to be a major priority right now. In an effort to reduce costs, Medicare has selected Novo Nordisk’s Wegovy for negotiations to lower prices under a law passed by a ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare and Medicaid beneficiaries.

The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Medicare Rights Center reports that President Trump’s executive order on prescription drug pricing supports key drug ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...